HEALTH● ELEVATED23h ago · Oct 14, 2026, 8:07 AM
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
equity_insider · united states of america · global
Global cancer drug spending reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, with colorectal and pancreatic cancers gaining prominence on research agendas as companies including Oncolytics Biotech, Revolution Medicines, Eli Lilly, Genmab, and Exelixis advance targeted therapies and combinations.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapunited states of america and nearby eventsMore from united states of americaLatest stories and threat level
More in Health
HEALTH8m agoPope Leo 'slept well' as his recovery continues, Vatican saysABC NewsHEALTH2h ago161 confirmed measles cases, one death reported in KozhikodeThe HinduHEALTH4h agoLongevity-first healthcare takes spotlight at Abu Dhabi Future Health SummitSouth China Morning PostHEALTH4h agoKenya’s Ebola cases test preparedness beyond NairobiAl Jazeera [en]